Walleye Capital LLC Acquires New Stake in Aquestive Therapeutics, Inc. $AQST

Posted by Stanley Muller on Aug 15th, 2026

Walleye Capital LLC acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 282,568 shares of the company’s stock, valued at approximately $1,175,000.

Other large investors have also bought and sold shares of the company. NewEdge Advisors LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets lifted its position in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares during the last quarter. Modern Wealth Management LLC bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth $33,000. Elevation Point Wealth Partners LLC bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth $42,000. Finally, ADAR1 Capital Management LLC increased its holdings in Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 264,000 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Aquestive Therapeutics

In related news, Director Julie Krop sold 25,000 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.81% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AQST. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer began coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and an average target price of $8.50.

View Our Latest Research Report on Aquestive Therapeutics

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.25 on Friday. The stock has a market capitalization of $533.43 million, a price-to-earnings ratio of -6.54 and a beta of 1.49. The company’s fifty day simple moving average is $4.14 and its two-hundred day simple moving average is $4.08. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. Equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.43 EPS for the current year.

Aquestive Therapeutics Company Profile

(Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.